Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AAPG Ascentage Pharma Group International	$41.95 -2.0%	$37.07	$16.50 ▼ $43.58	$3.66B	N/A	8,438 shs	6,168 shs
CXRXF ADVANZ PHARMA	$17.06	$17.06	$2.13 ▼ $18.00	$834.46M	N/A	11,851 shs	39 shs
HCM HUTCHMED	$15.00 -8.0%	$16.40	$11.51 ▼ $21.50	$2.62B	0.55	38,920 shs	129,176 shs
KYMR Kymera Therapeutics	$40.62 -0.6%	$45.11	$19.44 ▼ $53.27	$2.65B	2.18	524,846 shs	840,550 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AAPG Ascentage Pharma Group International	0.00%	+12.77%	+2.97%	+72.56%	+4,194,999,900.00%
CXRXF ADVANZ PHARMA	0.00%	0.00%	0.00%	0.00%	0.00%
HCM HUTCHMED	0.00%	-13.14%	-6.07%	+5.19%	-23.59%
KYMR Kymera Therapeutics	0.00%	-5.45%	-10.15%	+35.08%	+0.77%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AAPG Ascentage Pharma Group International	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CXRXF ADVANZ PHARMA	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
HCM HUTCHMED	3.1227 of 5 stars	3.3	4.0	0.0	0.0	2.9	0.0	1.9
KYMR Kymera Therapeutics	3.3468 of 5 stars	4.6	3.0	0.0	0.0	2.2	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AAPG Ascentage Pharma Group International	3.00	Buy	N/A	N/A
CXRXF ADVANZ PHARMA	0.00	N/A	N/A	N/A
HCM HUTCHMED	2.50	Moderate Buy	$28.00	86.67% Upside
KYMR Kymera Therapeutics	3.10	Buy	$59.11	45.52% Upside

Current Analyst Ratings Breakdown

Latest CXRXF, AAPG, HCM, and KYMR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/30/2025	KYMR Kymera Therapeutics	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$60.00
7/22/2025	HCM HUTCHMED	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$27.00 ➝ $28.00
7/15/2025	KYMR Kymera Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/3/2025	KYMR Kymera Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$70.00
6/27/2025	KYMR Kymera Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$56.00 ➝ $53.00
6/26/2025	KYMR Kymera Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$59.00
6/26/2025	KYMR Kymera Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$57.00 ➝ $53.00
6/26/2025	KYMR Kymera Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$54.00 ➝ $60.00
6/25/2025	KYMR Kymera Therapeutics	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$64.00
6/3/2025	KYMR Kymera Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$60.00
6/3/2025	KYMR Kymera Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$57.00 ➝ $64.00

(Data available from 8/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AAPG Ascentage Pharma Group International	$134.35M	27.24	N/A	N/A	$0.48 per share	87.40
CXRXF ADVANZ PHARMA	$525.58M	1.59	N/A	N/A	$0.16 per share	106.63
HCM HUTCHMED	$630.20M	4.15	$0.29 per share	52.22	$4.43 per share	3.39
KYMR Kymera Therapeutics	$47.07M	56.20	N/A	N/A	$12.90 per share	3.15

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AAPG Ascentage Pharma Group International	-$55.54M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
CXRXF ADVANZ PHARMA	-$74.86M	N/A	N/A	∞	N/A	-15.31%	N/A	-4.38%	N/A
HCM HUTCHMED	$37.73M	N/A	0.00	10.27	N/A	N/A	N/A	N/A	N/A
KYMR Kymera Therapeutics	-$223.86M	-$3.10	N/A	N/A	N/A	-409.07%	-30.11%	-25.65%	8/11/2025 (Estimated)

Latest CXRXF, AAPG, HCM, and KYMR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/11/2025	Q2 2025	KYMR Kymera Therapeutics	-$0.84	N/A	N/A	N/A	$17.37 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AAPG Ascentage Pharma Group International	N/A	N/A	N/A	N/A	N/A
CXRXF ADVANZ PHARMA	N/A	N/A	N/A	N/A	N/A
HCM HUTCHMED	N/A	N/A	N/A	N/A	N/A
KYMR Kymera Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AAPG Ascentage Pharma Group International	3.24	1.26	1.26
CXRXF ADVANZ PHARMA	257.04	2.39	1.61
HCM HUTCHMED	0.08	2.83	2.70
KYMR Kymera Therapeutics	N/A	8.49	8.49

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AAPG Ascentage Pharma Group International	N/A
CXRXF ADVANZ PHARMA	N/A
HCM HUTCHMED	8.82%
KYMR Kymera Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
AAPG Ascentage Pharma Group International	N/A
CXRXF ADVANZ PHARMA	N/A
HCM HUTCHMED	3.60%
KYMR Kymera Therapeutics	16.01%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AAPG Ascentage Pharma Group International	600	87.25 million	N/A	N/A
CXRXF ADVANZ PHARMA	429	48.91 million	N/A	Not Optionable
HCM HUTCHMED	1,811	174.42 million	168.14 million	Not Optionable
KYMR Kymera Therapeutics	170	65.12 million	54.69 million	Optionable

CXRXF, AAPG, HCM, and KYMR Headlines

Recent News About These Companies

Stocks With Rising Relative Price Strength: Kymera Therapeutics

August 6, 2025 | msn.com

Kymera Therapeutics to Report Second Quarter 2025 Financial Results on August 11, 2025

August 5, 2025 | finance.yahoo.com

TD Asset Management Inc Sells 26,468 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR)

August 3, 2025 | marketbeat.com

Victory Capital Management Inc. Cuts Stake in Kymera Therapeutics, Inc. (NASDAQ:KYMR)

August 3, 2025 | marketbeat.com

Equities Analysts Offer Predictions for KYMR Q2 Earnings

August 3, 2025 | americanbankingnews.com

Q2 Earnings Estimate for KYMR Issued By B. Riley

August 2, 2025 | marketbeat.com

B. Riley Begins Coverage on Kymera Therapeutics (NASDAQ:KYMR)

July 31, 2025 | marketbeat.com

Kymera Therapeutics, Inc. (KYMR) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

July 30, 2025 | zacks.com

Kymera Therapeutics (KYMR) to Release Quarterly Earnings on Wednesday

July 30, 2025 | marketbeat.com

Universal Beteiligungs und Servicegesellschaft mbH Trims Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR)

July 30, 2025 | marketbeat.com

Neo Ivy Capital Management Invests $395,000 in Kymera Therapeutics, Inc. (NASDAQ:KYMR)

July 27, 2025 | marketbeat.com

Jennison Associates LLC Sells 164,647 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR)

July 21, 2025 | marketbeat.com

Kymera Therapeutics (NASDAQ:KYMR) Upgraded at The Goldman Sachs Group

July 18, 2025 | marketbeat.com

Kymera Surges 70% in 3 Months: Buy, Sell or Hold the Stock?

July 18, 2025 | zacks.com

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Receives Average Recommendation of "Buy" from Analysts

July 17, 2025 | marketbeat.com

Kymera Therapeutics Inc (KYMR) - Investing.com

July 11, 2025 | investing.com

Kymera Therapeutics (KYMR) director group buys $13.9 million in stock

July 3, 2025 | investing.com

Tuesday’s Insider Activity: Major Buys and Sells Shake Up Markets

July 3, 2025 | investing.com

Insider Buying: Kymera Therapeutics, Inc. (NASDAQ:KYMR) Director Buys 317,167 Shares of Stock

July 2, 2025 | insidertrades.com

Bros. Advisors Lp Baker Purchases 655,500 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) Stock

July 1, 2025 | insidertrades.com

Kymera Therapeutics Announces Pricing of $250 Million Public Offering

June 26, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CXRXF, AAPG, HCM, and KYMR Company Descriptions

Ascentage Pharma Group International NASDAQ:AAPG

$41.95 -0.86 (-2.01%)

As of 08/8/2025 03:59 PM Eastern

Ascentage Pharma Group International Co., Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.

ADVANZ PHARMA OTCMKTS:CXRXF

$17.06 0.00 (0.00%)

As of 06/10/2021

ADVANZ PHARMA Corp. Limited, a pharmaceutical company, through its subsidiaries, owns or licenses a portfolio of branded and generic prescription products worldwide. The company operates through two segments: ADVANZ PHARMA International and ADVANZ PHARMA North America. Its ADVANZ PHARMA International segment offers a portfolio of branded and generic prescription products to wholesalers, distributors, hospitals, and pharmacies. This segment's products include Brinavess for the conversion of onset atrial fibrillation to sinus rhythm in adults; Aggrastat, a reversible GP IIb/IIIa inhibitor indicated for use in patients with acute coronary syndrome; Xydalba, a semi-synthetic lipoglycopeptide for the treatment of acute bacterial skin and skin structure infections in adults; and Zevtera/Mabelio, a cephalosporin antibiotic for the treatment of community-acquired and hospital-acquired pneumonia. The company's ADVANZ PHARMA North America segment provides Donnatal for the treatment of irritable bowel syndrome; Zonegran for the treatment of partial seizures in adults with epilepsy; Nilandron for the treatment of metastatic prostate cancer; Lanoxin for the treatment of mild to moderate heart failure and atrial fibrillation; Plaquenil for the treatment of lupus and rheumatoid arthritis; and Photofrin for the treatment of certain types of cancer. It also offers Prostaglandin E1 formulations for the treatment of erectile dysfunction and peripheral arterial occlusive disease under the Prostavasin, Viridal, Vasaprostan, and Edex brands, as well as holds licensed commercialization rights to a pre-registration drug/device combination product, Trevyent for the treatment of pulmonary arterial hypertension. It sells its products through direct sales and local distribution relationships. The company was formerly known as ADVANZ PHARMA Corp. and changed its name to ADVANZ PHARMA Corp. Limited in December 2019. ADVANZ PHARMA Corp. Limited is headquartered in London, the United Kingdom.

HUTCHMED NASDAQ:HCM

$15.00 -1.31 (-8.03%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$15.07 +0.07 (+0.47%)

As of 08/8/2025 07:41 PM Eastern

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The Other Ventures segment involves the other commercial businesses which include the sales, marketing, manufacture, and distribution of prescription drugs and healthcare products. The company was founded on December 18, 2000 and is headquartered in Hong Kong.

Kymera Therapeutics NASDAQ:KYMR

$40.62 -0.23 (-0.56%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$40.62 +0.01 (+0.01%)

As of 08/8/2025 04:14 PM Eastern

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time